Mode of Trial. 9.1. Prosecutors must have regard to the current Magistrates’ Court Sentencing Guidelines and the relevant Practice Direction when making submissions to the court about where the defendant should be tried.
Mode of Trial Sample Clauses
Related to Mode of Trial
Highlights WI-HER and RTI collaborated with NTDCP to conduct a GESI Pause and Reflect (P&R) meeting in Arusha from October 17-19, 2022. The meeting brought together the six councils (Ulanga DC, Mlimba DC, Longido DC, Monduli DC, Simanjiro DC and Kiteto DC) where the GESI behavior change activity was implemented in FY22 to document lessons learned and plan for GESI implementation in FY23. The meeting highlighted the importance of health education in addressing barriers to MDA uptake and involving government and traditional community leaders in MDA. Participants also discussed how to integrate GESI lessons learned into the CDD training package and potential activities for CCHPs. • Act | East supported the NTDCP to conduct a preparation meeting for the upcoming CCHP Pause and Reflect meeting in November. The preparation meeting was conducted in Singida from October 21-23, 2022. The technical team involved officers from PORALG, Directorate of Policy and Planning (DPP) office of the MOH, R4D, and WI-HER who collaboratively reviewed the meeting agenda, presentations, and documentation tools. During this preparation meeting, NTDCP and XXXXXX strongly recommended a high-level advocacy following the CCHP P&R meeting. This will be important for more resource mobilization at national and sub-national levels. Upcoming activities requiring COVID protocols: • Act | East will collaborate with NTDCP, DPP office of the MOH, and PORALG to conduct the CCHP P&R meeting from November 15-18 in Dodoma. The meeting will bring together district NTD coordinators and health secretaries from the 15 districts that implemented the CCHP activity in FY22 to gather feedback on the CCHP process, successes, challenges and way forward. • In collaboration with NTDCP and PORALG, Act | East will organize review and planning meetings for the districts and regions conducting trachoma and OV MDAs in FY23. The activity will be conducted in Morogoro from November 7-10, 2022 and will be followed by the training of trainers for trachoma and OV MDAs on November 11th. • Act | East will support the NTDCP to conduct SCH and STH MDA in 41 districts in November 2022. This MDA was postponed from FY22 Q4. • In collaboration with NTDCP, Act | East will conduct an LF disease-specific assessment (DSA) outcome investigation in Pangani DC and Kilwa DC in November. • Act | East Tanzania XXXXX staff will attend the NTD Information System (NIS) training in Mozambique from November 28 – December 3rd. • Act | East will support NTDCP and the National Institute for Medical Research (NIMR) Tanga lab to conduct analysis of Dried Blood Spot (DBS) samples collected in FY22 for OV using OV16 rapid diagnostic tests. COVID-19 data monitoring sources: WHO: xxxxx://xxxxx00.xxx.xxx/region/afro/country/tz October 2022 UGANDA Act | East Partner: RTI, The Xxxxxx Center, WI-HER, R4D, Save the Children Total population: 46,205,893 (2022) COP: [Redacted] Districts: 136 RTI HQ Team: [Redacted] Endemic diseases: LF (66), TRA (41), OV (43), SCH (91), STH (136) TABLE: Activities supported by USAID in FY23 LF OV Trachoma MDA N/A 8/11 districts (R1) 0/11 districts (R2) 0/2 districts (Dec 2022) 0/5 districts (June 2023) DSAs (#EUs) TAS 2: 0/8 EUs TAS 3: 0/3 EUs N/A TSS+: 2 EUs Confirmatory mapping: 2 districts XXXXX Targeted follow-up investigation in two districts of Nabilatuk and Buliisa Data quality assessment (DQA) in Buliisa district HSS High-level meeting on mainstreaming NTD drugs Building domestic resource mobilization capacity workshops National advocacy meeting Finalize and institutionalize GESI MDA training curriculum Finalize integration of GESI into MOH-led social and behavior change packages GESI behavior change activity scale up in two districts. Summary and explanation of changes made to table above since last month: N/A • Table is updated with planned FY23 activities. • OV MDA was completed in 8 districts by TCC. Ebola Update: • On 15 September, an index case of Ebola virus disease (EVD) was identified in Mubende District, Uganda. The Ministry of Health declared an outbreak of Sudan EVD on 20 September. As of 6 November, 135 cases have been confirmed throughout 7 districts. The CoP has weekly update meetings with HQ and HO and is actively monitoring the situation. We are developing SOPs and monitoring closely how the virus evolves within Uganda to be ready to change plans should Ebola be confirmed in our implementing districts. Highlights: RTI • Cross border Joint MDA Review Meeting. Act | East supported the RTI team to attend the Joint MDA review meeting in Kisumu, Kenya from 26–27 October. The objective of the meeting was to review progress and document learnings and gains from the previous joint MDA and to disseminate the MDA results. The meeting was attended by Senior MOH officials from both countries, district officials from border districts, Secretary for Health West Pokot County and partners. Some of the key recommendations were (1) to delay trachoma impact survey in West Pokot for 1 more round of MDA to have a joint impact survey with Uganda to realize intended outcomes; (2) Kenya adopting house to house approach of MDA implementation with VHTs; and
Synopsis The agreement authorizes the parties to charter space between South Korea, Japan and the U.S. Pacific Coast. Dated: March 28, 2008. By Order of the Federal Maritime Commission. Xxxxx X. Xxxxxxx, Assistant Secretary. [FR Doc. E8–6796 Filed 4–1–08; 8:45 am] BILLING CODE 6730–01–P FEDERAL MARITIME COMMISSION Ocean Transportation Intermediary License Applicants Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for license as a Non-Vessel Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR part 515). Persons knowing of any reason why the following applicants should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573. Non-Vessel Operating Common Carrier Ocean Transportation Intermediary Applicants: American International Shipping, 0000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxx, XX 00000. Officers: Xxxxxxx Xxxxxx, President, (Qualifying Individual), Xxxxx Xxxxxxx, Vice President. Freight Masters Overseas, Inc., 8177 XX 00 Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxx X. Xxxxxxx, Managing Director, (Qualifying Individual), Xxxxxxxx Xxxxxxxxx, President. ARC Air Logistics, Inc., 156–15 146th Avenue, Jamaica, NY 11434. Officers: Xxxxxxx Xxxxxxx, President, (Qualifying Individual), Xxxxx Xxxxxxxxx, Secretary. Pacer Container Line, Inc., 0000 Xxxxxxxxx Xxxxx, Xxxxxx, XX 00000. Officers: Xxxxxxx X. Xxxx, Vice President, (Qualifying Individual), Xxxxxxx X. Xxxxxxxxx, President. Airway Express & Hyundai Express, 000 Xxxxxx Xxxx, Burlingame, CA 94010. Xxx Xxxx Xxxx, Sole Proprietor. Transeagle Cargo Logistics Corp., 0000 Xxxx 00 Xxxxxx, Xxxxxxx, XX 00000. Officers: Xxxxxx Xxxxx, Vice President, (Qualifying Individual), Xxxxx Xxxxxxxxx, President. Non-Vessel Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicant: ACS Logistics USA Inc., 0 Xxxxxxxx Xxx, Xxxxxxxxx, XX 00000.
Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.
Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.
Plan Brochure The Hospital will pay 75% of the billed premium towards coverage of eligible employees under the long-term disability portion of the Plan (HOODIP or an equivalent plan as described in the August, 1992 booklet (Part B)), the employee paying the balance of the billed premium through payroll deduction. For the purpose of transfer to the short- term portion of the disability program, employees on the payroll as of the effective date of the transfer with three (3) months or more of service shall be deemed to have three (3) months of service. For the purpose of transfer to the long- term portion of the disability program, employees on the active payroll as of the effective date of the transfer with one (1) year or more of service shall be deemed to have one (1) year of service.
Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.
Protocol No action to coerce or censor or penalize any negotiation participant shall be made or implied by any other member as a result of participation in the negotiation process.
Diagnostic Assessment 6.3.1 Boards shall provide a list of pre-approved assessment tools consistent with their Board improvement plan for student achievement and which is compliant with Ministry of Education PPM (PPM 155: Diagnostic Assessment in Support of Student Learning, date of issue January 7, 2013).
Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).
Information Submission by Participating TO The initial information submission by the Participating TO shall occur no later than one hundred eighty (180) Calendar Days prior to Trial Operation and shall include the Participating TO’s Transmission System information necessary to allow the Interconnection Customer to select equipment and meet any system protection and stability requirements, unless otherwise agreed to by the Participating TO and the Interconnection Customer. On a monthly basis the Participating TO shall provide the Interconnection Customer and the CAISO a status report on the construction and installation of the Participating TO’s Interconnection Facilities and Network Upgrades, including, but not limited to, the following information: (1) progress to date; (2) a description of the activities since the last report; (3) a description of the action items for the next period; and (4) the delivery status of equipment ordered.
